PROTEOMIC PROFILE AND NON-SPECIFIC IMMUNOPROPHYLAXIS OF RESPIRATORY DISEASES IN FREQUENTLY SICK CHILDREN

Cover Page

Abstract


We have investigated efficacy of meglumine acridonacetate (Cycloferon) in frequently sick children (FSC) on the basis of serum proteomic profile dynamics; we have also studied epidemiologic efficacy of interferon inductor as a mean of non-specific immunoprophylaxis. FSC were subjects to follow up during 4–10 years. We have used recommended regimens of drug administration. Were analyzed: anamneses of FSC, clinical symptoms, infectious index calculation, stratification of children into 5 groups of FSC and separation of children with truly frequent recurrent respiratory viral diseases. On the basis of proteomic blood analyzes the following parameters of efficacy of treatment with meglumine acridonacetate were defined: expression intensity of Rho- and Ras-signaling pathways proteins. Epidemiologic efficacy of the drug was 2,9 (from 2,4 to 3,4), rate of protection — 62,8% (58,5–67,1%).


I. V. Sarvilina

Medical centre «Novomeditsina», Rostov-on-Don

Author for correspondence.
Email: isarvilina@mail.ru

Russian Federation директор медицинского центра «Новомедицина», доктор медицинских наук Адрес: 344007, Ростов-на-Дону, ул. Социалистическая, д. 74 Тел.: (903) 436-48-66

M. G. Romantsov

Metchnikov North-western state medical university, St. Petersburg

Email: mr@nextnail.ru

Russian Federation доктор медицинских наук, профессор кафедры педиатрии и детской кардиологии ГОУ ВПО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Адрес: 195067, Санкт-Петербург, Пискаревский проспект, д. 47 Тел.: (921) 967-69-48

  1. Romantsov M.G. Chasto boleyushchie deti: sovremennaya farmakoterapiya [Frequently ill children: modern pharmacotherapy]. Moscow, 2009. 349 p.
  2. Makarova Z.S., Golubeva L.S. Ozdorovlenie i reabilitatsiya chasto boleyushchikh detei [Health Improvement and Rehabilitation of Frequently Ill Children]. Moscow, 2004. 321 p.
  3. Samsygina G.A. Frequently ill children: problems of pathogenesis, diagnostics and therapy. Pediatriya = Pediatrics. 2005; 1: 66–74.
  4. Voevodin D. A. Zhurnal mikrobiologii = Journal of microbiology. 2005; 2: 89–92.
  5. Diagnostika, differentsial'naya diagnostika i lechenie detskikh infektsii pod red. V.M. Timchenko, V.V. Levanovicha, I.B. Mikhailova [Diagnosis, Differential Diagnosis and Treatment of Child Infections. Edited by V.M. Timchenko, V.V. Levanovich, I.B. Mikhailov]. St. Petersburg, 2004. 430 p.
  6. Romantsov M.G. Respiratornye zabolevaniya u detei [Respiratory Diseases in Children]. Moscow, 2003. 137 p.
  7. Ershov F.I., Kiselev O.I. Interferony i ikh induktory (ot molekul do lekarstv) [Interferon and Its Inducers (from molecules to medicine)]. Moscow, 2005. 340 p.
  8. Ershov F.I., Romantsov M.G. Antivirusnye sredstva v pediatrii [Antiviral Drugs in Pediatrics]. Moscow, 2005. 243 p.
  9. Gorshkova Yu.V., Tregubov A.V., Sarvilina I.V. Biomeditsina = Biomedicine. 2006; 3: 121–122.
  10. Garashchenko M.V. Novye tekhnologii v medikamentoznoi profilaktike ORZ u detei shkol'nogo vozrasta v usloviyakh megapolisa. Avtoref. dis. ...kand. med. nauk [New Technologies in the Prevention of Acute Respiratory Disease in School-age Children in a Metropolis. Author’s abstract]. Moscow, 2007. 21 p.
  11. Kondrat'eva E.I. Vestnik Sankt-Peterburgskoi gosudarstvennoi meditsinskoi akademii im. I.I. Mechnikova = Bulletin of I.I. Mechnikov St. Petersburg State medical Academy. 2009; 1: 148−153.
  12. Shul'dyakova O.G. Kliniko-immunologicheskaya i profilakticheskaya effektivnost' tsikloferona v otnoshenii ORVI v organizovannykh kollektivakh. Avtoref. dis. …kand. med. nauk [Clinical-immunological and Prophylactic Efficacy of Cycloferon in Acute Respiratory Viral Infection among Organized Groups. Author’s abstract]. Saratov, 2007. 23 p.

Views

Abstract - 23

PDF (Russian) - 6

Cited-By


PlumX



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies